Paradigm Biopharmaceuticals Ltd (ASX: PAR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Paradigm Biopharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar. Market Cap $298.68 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 235.95 million
Earnings per share -0.193
Dividend per share N/A
Year To Date Return -27.59%
Earnings Yield N/A
Franking N/A
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Paradigm Biopharmaceuticals Ltd (ASX: PAR)
Latest News
Share Fallers
Why Beach, Bendigo and Adelaide Bank, Opthea, and Paradigm shares are sinking
Capital Raising
Paradigm Biopharmaceuticals share price freefalls 27% following $66m cap raise
Capital Raising
Up 90% in 2 weeks, here’s why the Paradigm share price has been halted
Share Gainers
Why Appen, Imugene, OZ Minerals, and Paradigm shares are charging higher
Healthcare Shares
Why is the Paradigm Biopharmaceuticals share price up 12% on Monday?
Healthcare Shares
Why is the Paradigm share price surging 7% today?
Index investing
ASX 200 healthcare shares provided some pain relief today. Here’s why
Healthcare Shares
Why is the Paradigm share price rocketing 20% higher today?
PAR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Paradigm Biopharmaceuticals Ltd
Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) forthe lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).
PAR Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 17 Aug 2022 | $1.36 | $-0.10 | -6.85% | 1,684,987 | $1.45 | $1.45 | $1.36 |
| 16 Aug 2022 | $1.46 | $0.04 | 2.82% | 880,721 | $1.45 | $1.50 | $1.42 |
| 15 Aug 2022 | $1.42 | $-0.55 | -27.91% | 2,126,754 | $1.58 | $1.58 | $1.42 |
| 10 Aug 2022 | $1.97 | $-0.15 | -7.06% | 780,090 | $2.10 | $2.10 | $1.87 |
| 09 Aug 2022 | $2.12 | $0.23 | 12.16% | 1,266,198 | $1.92 | $2.15 | $1.92 |
| 08 Aug 2022 | $1.89 | $0.18 | 10.54% | 1,032,505 | $1.89 | $1.96 | $1.81 |
| 05 Aug 2022 | $1.71 | $0.21 | 14.01% | 663,368 | $1.50 | $1.75 | $1.50 |
| 04 Aug 2022 | $1.50 | $-0.08 | -5.07% | 1,516,364 | $1.67 | $1.79 | $1.42 |
| 03 Aug 2022 | $1.58 | $0.20 | 14.49% | 1,585,655 | $1.41 | $1.80 | $1.41 |
| 02 Aug 2022 | $1.38 | $0.15 | 12.18% | 600,949 | $1.24 | $1.43 | $1.24 |
| 01 Aug 2022 | $1.23 | $0.11 | 9.81% | 570,348 | $1.13 | $1.32 | $1.13 |
| 29 Jul 2022 | $1.12 | $0.08 | 7.67% | 282,039 | $1.05 | $1.14 | $1.04 |
| 28 Jul 2022 | $1.04 | $0.02 | 1.96% | 140,186 | $1.03 | $1.06 | $1.02 |
| 27 Jul 2022 | $1.02 | $-0.05 | -4.64% | 150,885 | $1.07 | $1.07 | $1.02 |
| 26 Jul 2022 | $1.08 | $0.02 | 1.90% | 115,706 | $1.05 | $1.08 | $1.04 |
| 25 Jul 2022 | $1.05 | $0.00 | 0.00% | 153,587 | $1.05 | $1.09 | $1.04 |
| 22 Jul 2022 | $1.05 | $-0.01 | -0.94% | 107,148 | $1.07 | $1.07 | $1.05 |
| 21 Jul 2022 | $1.07 | $0.02 | 1.91% | 349,363 | $1.05 | $1.12 | $1.05 |
| 20 Jul 2022 | $1.05 | $0.04 | 3.99% | 116,175 | $1.04 | $1.05 | $1.01 |
| 19 Jul 2022 | $1.00 | $-0.03 | -2.89% | 208,379 | $1.03 | $1.05 | $1.00 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 08 Mar 2022 | Paul Rennie | Buy | 48 | $50,634 | On-market trade. |
| 25 Jan 2022 | Donna Skerrett | Buy | 375 | $708,750 | As advised by the company. Employee Share Plan |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Helen E Fisher | Non-Executive Director | Feb 2021 | Ms Fisher is Chief Executive Officer and managing director of Bio Capital Impact Fund (BCIF) and Non-Executive Director (NED) and Chair of the Audit and Risk Management Committee of Calix Limited (ASX: CXL), a company with a platform technology with applications in climate change, water management, biotech, and pharmaceutical areas. Prior to establishing BCIF, she was a partner of Deloitte and led Deloitte's life science practice in Australia for 5 years, having had many years' experience in the life sciences and health care sector. |
| Mr Paul Rennie | Managing DirectorInterim Chairman | May 2014 | Mr Rennie has sales, marketing, business development, operational and IP commercialisation experience in the biopharmaceutical sector. His experience includes working for Boehringer Mannheim (now Roche Diagnostics), Merck KGGA as National Sales and Marketing Manager and Soltec (FH Faulding Ltd) as their Director of business development. He also led the commercialisation of Recaldent a novel biopharmaceutical arising from research at the dental school, University of Melbourne. Paul took an R&D project from the laboratory bench to a commercial product now marketed globally as an additive to oral care products. More recently he worked in a number of positions with Mesoblast Ltd. He was the inaugural COO and moved into Executive Vice President New Product Development for the adult stem cell company. For the past 4 years, he has worked full time at Paradigm Biopharmaceuticals Limited |
| Mr Amos Meltzer | Non-Executive Director | Dec 2020 | Mr Meltzer is a scientist and an intellectual property lawyer with over 25 years of experience in international trade and in commercialising technologies principally in the life sciences sector. He has presided over life science research and product development projects clinical trials as well as the commercialisation of life sciences assets through both licensing and the sale and marketing of a pharmaceutical product. Previously, he has served as in house counsel and IP director at two Nasdaqlisted companies Compugen and Gilat, as a non-executive director of a biotechnology company Evogene and as VP of Business Development and then CEO of an ASX-listed biopharmaceutical company Immuron. He currently serves as Chief Operating Officer of neuro-medical device company Synchron, chairman of the board of surgeons' education services company Vasculab and as a legal advisor to a number of ASX listed and private life science companies. |
| Mr John Gaffney | Non-Executive Director | Sep 2014 | Mr Gaffney LL.M is a lawyer with over 30 years' experience and has undertaken the AICD Company Directors qualification. He brings to the Board a compliance and corporate governance background and is experienced in financial services compliance. He also has corporate and commercial experience having worked with a major national law firm as a senior lawyer and also practised as a barrister at the Victorian Bar. Previously Mr Gaffney has been a Non-Executive Director of a US based biotechnology company and SelfWealth Ltd. |
| Dr Donna Skerrett | Executive Director | Jul 2020 | Dr Skerrett, has more than 30 years' experience in transfusion medicine, cellular therapy, and transplantation. She brings a wealth of experience in medical, clinical, and regulatory affairs. Donna served previously as Chief Medical Officer at Mesoblast. She was Director of Transfusion Medicine and Cellular Therapy at Weill Cornell Medical Center in New York, and prior to that was Associate Director of Transfusion Medicine and Director of Stem Cell Facilities at Columbia University's New York-Presbyterian Hospital. She has previously chaired the New York State Council on Blood and Transfusion Services, and served on the Board of Directors of the Fox Chase Cancer Center in Philadelphia |
| Mr Kevin G Hollingsworth | Company Secretary | - | |
| Mr Marco Polizzi | Chief Executive Officer | Jul 2022 | - |
| Marco Polizzi | Chief Executive Officer | - | |
| Kevin G Hollingsworth | Company Secretary | - |
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 20,484,777 | 8.92% |
| Kzee Pty Ltd <Kzee Superannuation Fund A/C> | 10,781,467 | 4.70% |
| Paul John Rennie | 8,230,400 | 3.58% |
| Cs Third Nominees Pty Limited <HSBC Cust Nom Au Ltd 13 A/C> | 4,349,240 | 1.89% |
| Nancy Edith Wilson-Ghosh <Ghosh Family A/C> | 3,860,835 | 1.68% |
| Citicorp Nominees Pty Limited | 3,852,323 | 1.68% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> | 3,594,952 | 1.57% |
| J P Morgan Nominees Australia Pty Limited | 3,571,937 | 1.56% |
| Mr Evan Philip Clucas + Ms Leanne Jane Weston <Kuranga Nursery Super A/C> | 2,627,913 | 1.14% |
| V Redford Pty Ltd <Redford S/F A/C> | 2,423,500 | 1.06% |
| Mr Brett Langan | 2,303,432 | 1.00% |
| Mjgd Nominees Pty Ltd <Bsmi A/C> | 1,983,849 | 0.86% |
| BNP Paribas Noms Pty Ltd <Drp> | 1,871,447 | 0.82% |
| Jgm Investment Group Pty Ltd <Muchnicki Family A/C> | 1,737,408 | 0.76% |
| Ms Lenna Yu Ling Tye | 1,521,631 | 0.66% |
| Australian Executor Trustees Limited <No 1 Account> | 1,512,100 | 0.66% |
| BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> | 1,285,072 | 0.56% |
| Ten Luxton Pty Ltd <Abotomey S/F A/C> | 1,200,000 | 0.52% |
| View 26 Pty Ltd <View 26 A/C> | 1,150,050 | 0.50% |
| Hot Springs Superannuation Pty Limited <Hot Springs P/L S/F A/C> | 1,132,910 | 0.49% |